I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Ritlecitinib, o novo fármaco aprovado pelo FDA para o trata..:
Man Chin, Chung
;
Longhin Bosquesi, Priscila
;
Perez Orrico, Silvana Regina
ULAKES JOURNAL OF MEDICINE. 3 (2023) 2 - p. , 2023
Link:
https://doi.org/10.56084/ulakesjmed.v3i2.892
RT Journal T1
Ritlecitinib, o novo fármaco aprovado pelo FDA para o tratamento de alopecia areata grave em adolescentes e adultos
UL https://suche.suub.uni-bremen.de/peid=cr-10.56084_ulakesjmed.v3i2.892&Exemplar=1&LAN=DE A1 Man Chin, Chung A1 Longhin Bosquesi, Priscila A1 Perez Orrico, Silvana Regina PB Uniao das Faculdades dos Grandes Lagos YR 2023 SN 2764-0671 JF ULAKES JOURNAL OF MEDICINE VO 3 IS 2 LK http://dx.doi.org/https://doi.org/10.56084/ulakesjmed.v3i2.892 DO https://doi.org/10.56084/ulakesjmed.v3i2.892 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)